| Literature DB >> 35056915 |
Daniel Ion1,2, Adelina-Gabriela Niculescu3, Dan Nicolae Păduraru1,2, Octavian Andronic1,2, Florentina Mușat1,2, Alexandru Mihai Grumezescu3,4,5, Alexandra Bolocan1,2.
Abstract
Cancer represents one of the leading causes of morbidity and mortality worldwide, imposing an urgent need to develop more efficient treatment alternatives. In this respect, much attention has been drawn from conventional cancer treatments to more modern approaches, such as the use of nanotechnology. Extensive research has been done for designing innovative nanoparticles able to specifically target tumor cells and ensure the controlled release of anticancer agents. To avoid the potential toxicity of synthetic materials, natural nanoparticles started to attract increasing scientific interest. In this context, this paper aims to review the most important natural nanoparticles used as active ingredients (e.g., polyphenols, polysaccharides, proteins, and sterol-like compounds) or as carriers (e.g., proteins, polysaccharides, viral nanoparticles, and exosomes) of various anticancer moieties, focusing on their recent applications in treating diverse malignancies.Entities:
Keywords: chemotherapeutic agents targeted delivery; natural anticancer compounds; natural cancer therapies; natural nanocarriers; natural nanoparticles; novel cancer treatment alternatives
Year: 2021 PMID: 35056915 PMCID: PMC8779479 DOI: 10.3390/pharmaceutics14010018
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Limitations of conventional cancer treatment strategies. Created based on information from [13,20,21,22,23,24,25].
Figure 2NPs roles in regulating TME and improving tumor immunotherapy. Created based on information from [1,30,34,35,36]. Abbreviations: APCs—antigen-presenting cells; DCs—dendritic cells; TME—tumor microenvironment; ECM—extracellular matrix; MHC—major histocompatibility complex; CTL—cytotoxic T lymphocyte.
Figure 3Polyphenols classification and examples. Created based on information from [44,45,46].
Figure 4Baicalein anticancer activity by binding to and interacting with specific cellular targets. Reprinted from an open-access source [63].
Figure 5EGCG delivery possibilities for cancer therapy: (1) incorporation of ligands on NPs surface for specific targeting of cancer cell receptors or antigens; (2) EGCG used as a capping agent; (3) surface functionalization with polymers for improving drug release, cellular uptake, and intestinal absorption; (4) co-encapsulation with conventional chemotherapeutic agents. Reprinted from an open-access source [66].
Examples of anticancer nanoparticle formulation based on resveratrol.
| Nanoformulation | Physicochemical | Type(s) of Cancer | Observations | Refs. |
|---|---|---|---|---|
| RES-conjugated gold NPs |
Shape: spherical Average core size: 16.1 ± 5.0 nm Zeta potential: −25 mV | Breast cancer |
Enhanced bioavailability of RES Excellent loading of RES with subsequent efficient antitumor effects Synergic anticancer activity due to dual action of gold and RES | [ |
| RES-loaded SLNs |
Shape: spherical Average diameter: 168 ± 10.7 nm Zeta potential: −23.5 ± 1.6 mV Loading capacity: 25.2 ± 1.7% | Breast cancer |
Enhanced bioavailability and anticancer activity of RES Cell proliferation inhibited in a dose-dependent manner Lower IC50 values for RES-SLNs than for free RES Increased cell cycle arrest in the G0/G1 phase via CyclinD1 downregulation in cancer cells | [ |
| Chitosan-coated-trans-RES and ferulic acid loaded SLNs conjugated with folic acid |
Shape: spherical Average diameter: 174 ± 5 nm Zeta potential: −25.9 mV | Colon cancer |
Good stability under acidic conditions Effectively involved and increased cytotoxicity in cancer cells, resulting in apoptosis induction Cancer cells specific delivery; induced cell death of HT-29 cell line but did not affect normal NIH 3T3 cells | [ |
| RES-loaded in functionalized MSNs |
Shape: spherical Average diameter: ~60 nm | Prostate cancer |
Significant control over RES release at 5.5 pH Robust and dose-dependent sensitization of Docatexal in hypoxic cell environment Enhanced antiproliferative potential | [ |
| RES-loaded PLGA NPs |
Shape: spherical Average diameter: 237.8 ± 4.93 nm Encapsulation efficiency: 89.32 ± 3.51% | Prostate cancer |
Significant decrease cell viability with IC50 and IC90 of 15.6 ± 1.49 and 41.1 ± 2.19 μM, respectively Significantly greater cytotoxicity than free RES Anticancer effects mediated by apoptosis; confirmed by cell cycle arrest at G1-S transition phase, DNA nicking, loss of mitochondrial membrane potential, ROS generation, and externalization of phosphtidylserine | [ |
| RES-loaded gelatin NPs |
Shape: spherical Average diameter: 294 nm Encapsulation efficiency: 93.6% | Non-small cell lung cancer |
Superior efficacy in NCI-H460 cells Induced apoptosis via alteration in expression of p53, p21, caspase-3, Bax, Bcl-2 and NF-κB Induced cell arrest in the G0/G1 phase of cell cycle | [ |
| RES-cyclodextrin complex-loaded PLGA NPs |
Shape: spherical Average diameter: 264.2 ± 3.4 nm | Non-small cell lung cancer |
Improved RES aqueous solubility by 66-folds Intensified anticancer effects compared to free RES Enhanced cellular uptake, cytotoxicity, and apoptosis Very good aerosolization potential | [ |
Figure 6Anticancer effects of curcumin. Created based on information from [39,97].
Examples of anticancer nanoparticle formulations based on curcumin.
| Nanoformulation | Physicochemical | Type(s) of | Observations | Refs. |
|---|---|---|---|---|
| CUR-conjugated with HSA |
Shape: spherical Average diameter: 180 ± 2nm Zeta potential: −7mV Loading capacity: 12% Encapsulation efficiency: 70% | Breast cancer |
Enhanced stability of CUR both in physiological and acidic conditions Significant increase in CUR cytotoxicity on cancer cells without increasing the toxicity on healthy cells | [ |
| CUR and liquid fluorocarbon perfluorohexane (PHF) co-loaded in ferritin nanocages conjugated with folic acid |
Shape: spherical Average diameter: 47 nm Zeta potential: −37mV CUR loading ratio: 125.8 ± 2.1% | Ovarian cancer |
Significant tumor treatment effects Under low-intensity focused ultrasound (LIFU) and 5.0 pH, the nanoplatform released 53.2% of encapsulated drugs in 24 h After 4 min of LIFU at 5.0 pH, the system provided contrast-enhanced ultrasound imaging capabilities | [ |
| CUR-loaded chitosan NPs |
Shape: spherical Average diameter: 115 ± 21 nm Zeta potential: 33.8mV Loading capacity: 21.6% Encapsulation efficiency: 83.8% | Colon cancer |
CUR was mostly released in the first 5 h then gradually released up to 90 h Higher release in pH 5.2 than in pH 7 Time-dependent decrement of cancer cells viability After 96 h of exposure 67.6% HCT-116 cells and 73.8% A-546 cells were dead | [ |
| CUR-loaded chitosan NPs |
Shape: spherical Average diameter: 415.30 ± 9.03 nm Zeta potential: 33.37 ± 0.21 mV Encapsulation efficiency: 73.56 ± 6.01% | Lung cancer |
Effective and precisely controllable NPs induced cytotoxicity only upon irradiation with 457 nm LED light NPs Upon photoactivation, CUR induced chromatin condensation and DNA fragmentation leading to cancer cells destruction | [ |
| CUR-loaded silk fibroin NPs |
Shape: spherical Average diameter: 155–175 nm Zeta potential: −45 mV | Hepatocellular carcinoma |
Local long-term sustained drug delivery Cytotoxicity against cancer cells, while no decreasing viability reported for healthy cells Higher efficacy against neuroblastoma cells than against hepatocellular carcinoma cells | [ |
| CUR-loaded soybean polysaccharide nanocapsules |
Shape: spherical Average diameter: 200–300 nm Encapsulation efficiency: ~90% | Colon cancer |
No significant difference in the viability of HCT 116 and MCF-7 cells challenged with DMSO-dissolved and nanoencapsulated CUR Most of antiproliferative activity of the nanosystem manifested after sim, ulated gastric and intestinal digestions | [ |
| CUR-loaded PEGylated MSNs |
Shape: spherical Average diameter: 197 nm Loading capacity: 8.1% Encapsulation efficiency: 89.1% | Cervical cancer |
Significantly increased solubility and enhanced bioavailability of CUR for photodynamic therapy Smooth and steady release at physiological pH, while at 5.0 pH the release rate was slightly speeded up | [ |
| CUR-loaded poloxamer188- |
Shape: spherical Average diameter: 100 nm | Esophageal squamous carcinoma |
Improved in vitro antioxidant activity compared to crude CUR powder Particles could biodistribute into liver, kidney, and lung tissues, acting as protection agents in cancer radiotherapy | [ |
| CUR-loaded therapeutic lipid NPs |
Shape: spherical Average diameter: 19.8 ± 4.2 nm | Nasopharyngeal carcinoma (NPC) |
Effective targeting ability, suppressed cellular proliferation, and induced apoptosis in vitro Enhanced inhibitory effect on NPC tumor growth and metastasis in vivo | [ |
| CUR-loaded in niosomal NPs |
Shape: spherical Average diameter: ~60 nm Zeta potential: −35 mV | Glioblastoma |
Dose-dependent decrease in cell proliferation and viability of glioblastoma stem-like cells (GSC) Higher effects on GSC viability, apoptosis, cell cycle arrest, and expression of Bax than free CUR Significantly impaired GSC migration | [ |
Figure 7Overview of the main discussed categories of natural nanocarriers for cancer management.
Advantages and disadvantages of main discussed natural nanocarriers for cancer management.
| Nanocarrier Type | Examples | Advantages | Disadvantages | Refs |
|---|---|---|---|---|
| Proteins | Albumin, keratin, silk fibroin, silk sericin, ferritin |
Inherent targeting potential Increased cellular uptake Good affinity to anticancer drugs High drug-binding capacity High stability Possibility of self-assembly Ease of functionalization Possibility of use in photodynamic therapy |
Batch-to-batch variations Low yields High costs Some may cause in vivo inflammation | [ |
| Polysaccharides | Chitosan, fucoidan, |
Wide availability Ease of production Ease of functionalization Possibility of developing multifunctional carriers Some may act as targeting agents High stability Possibility of use in photodynamic therapy |
Complicated manufacturing process Unclear metabolism in the body Poor solubility in common solvents | [ |
| Viral NPs | Cowpea mosaic |
Enhanced multifunctional group display Some offer the possibility to treat platinum-resistant cancers Possibility of use in photodynamic therapy Can be used for intravital imaging, drug and gene delivery, and immunotherapy |
Difficult to predict in vivo behavior; each viral-based delivery system must be evaluated on a case-by-case basis prior to clinical testing | [ |
| Exosomes | Bovine milk |
High loading capacity for drugs and genes High stability Inherent targeting potential Excellent tumor cell uptake High specificity to tumor-associated cells Enhanced permeability and retention effect Can be employed in cancer diagnosis |
Lack of consensus on the best method for obtaining high yields of pure exosomes Challenging to load cargos and targeting agents without corrupting exosomes | [ |
| Biomimetic NPs | NPs coated with the membranes of red blood cells, white blood cells, platelets, macrophages, bacterial cells, stem cells, cancer cells |
Unique construction Long lifespan Excellent targeting ability Enhanced drug retention Retained cytotoxicity to cancer cells |
Some may raise immunogenicity concerns Challenging translation from bench to bedside Complex preparation process Low yields | [ |